Meilahti Hospital
- Address
- P. O. Box 340, 00029 Helsinki, Finland
Cardiovascular Diseases
The Hematology department at Meilahti Hospital is conducting research focused on heart health, evaluating whether dual antiplatelet therapy can lower the risk of major adverse cardiovascular events after coronary surgery in patients with acute coronary syndrome.
- Dual antiplatelet therapy after coronary artery bypass grafting
- Risk reduction of cardiovascular complications
- Management of multi‑vessel coronary disease
This work aims to improve post‑operative outcomes for individuals undergoing heart procedures.
Immune System Diseases
Studies at the site explore treatments for systemic juvenile idiopathic arthritis and the performance of new vaccines, including a 21‑valent pneumococcal conjugate vaccine and a pentavalent meningococcal ABCYW vaccine, to define optimal dosing and immune protection in children.
- Dose‑finding for sarilumab in pediatric arthritis
- Immunogenicity comparison of PCV21 versus 15‑valent vaccine
- Safety and antibody response of MenPenta formulations
- Vaccination schedules for infants and toddlers
The goal is to establish effective, safe therapies and vaccination strategies for young patients.
Nervous System Diseases
A trial investigates a novel agent, VRG50635, in adults with amyotrophic lateral sclerosis, including both sporadic and familial forms, to assess long‑term safety and potential disease‑modifying effects.
- Investigational therapy for ALS
- Long‑term safety monitoring
- Targeting neurodegeneration in adult patients
This research seeks new treatment options for a currently incurable neurodegenerative condition.
Bacterial Infections and Mycoses
The hospital conducts immunization studies on meningococcal immunization and pneumococcal immunization, evaluating the immune response and safety of new vaccine formulations across infants, toddlers, and children.
- Evaluation of MenPenta vaccine across age groups
- Comparative immunogenicity of PCV21 versus 15‑valent vaccine
- Serum bactericidal activity assessment
- Safety profiling of new vaccine formulations
These projects aim to strengthen protection against serious bacterial infections in the pediatric population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 4 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Sanofi Pasteur Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Meilahti Hospital
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults | Sanofi Pasteur | Phase II | Not Recruiting | Oct 2021 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2018-06-08 | 2018-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.